Oncology

Therapeutics, diagnostics and evidence shaping cancer care.

NSCLC oncogenic mutations push targeted therapy deeper into clinical practice

A review outlines how oncogenic mutations guide NSCLC therapy, with emphasis on TKI selection, CNS control, resistance, and biomarker development.

Trial pauses have sharpened scrutiny of autoimmune CAR T cells, as early remission data collide with concerns about…

Review in Gut traces systemic therapy advances in metastatic colorectal cancer and why stromal targeting may help microsatellite…

A JCO abstract flags high body-mass index as an emerging cancer mortality challenge in the U.S., but the…

An ASCO/JCO study examines how interpretable gene methods map epithelial-mesenchymal transition and immune niches in non-small cell lung…

The scraped JCO feed provides only a truncated title for a GO306 oncolytic vaccinia virus trial, with no…

First-in-human phase 1/2 study of ASKG915 examines an anti-PD-1/pro-IL-15 fusion protein, but no abstract data were provided in…

AmpliconSuite identifies ecDNA, breakage–fusion–bridge events and other amplification modes in cancer WGS, with validation in 72 models.

A marine Streptomyces isolate from Red Sea sediment produced a melanin-like pigment that increased yield and showed in…

A systematic review found mothers were the most common supporter in teen and young adult cancer visits, with…

Oncology

Therapeutics, diagnostics and evidence shaping cancer care.

In Brief The 5-minute rounds